Supernus Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
SUPN Supernus Pharmaceuticals Inc
CRS Carpenter Technology Corp
AMWL American Well Corp
DGLD.NV Credit Suisse AG
HMPQ HempAmericana Inc
$SPMCKCP S&P GSCI Coffee Multiple Contract (U
WYNN Wynn Resorts Ltd
BAC Bank of America Corp
KNDI Kandi Technologies Group Inc
$RFTREES Refinitiv Eurozone ESG Select Index
Go

Health Care : Pharmaceuticals | Small Cap Blend
Company profile

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy. In addition, it is developing multiple product candidates in psychiatry to address unmet medical needs and market opportunities for the treatment of impulsive aggression (IA) and for the treatment of attention deficit hyperactivity disorder (ADHD). It is developing SPN-810 (molindone hydrochloride) to treat IA in patients having ADHD. It is developing SPN-812 (viloxazine hydrochloride) as a candidate to treat patients having ADHD. The Company's neurology portfolio consists of Oxtellar XR and Trokendi XR, which are the first once-daily extended release oxcarbazepine and topiramate products, respectively, indicated for epilepsy in the United States market.

Postmarket

Last Trade
Delayed
$29.20
-0.02 (-0.07%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$29.22
Day's Change
0.43 (1.49%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
29.80
Day's Low
28.49
Volume
(Above Average)
Volume:
690,133

10-day average volume:
582,146
690,133

Display:

Providers:

UpdateCancel
6 providers
January 06, 2021
Supernus to Present at J.P. Morgan 39th Annual Healthcare Conference

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company's management will present at the...(Globe Newswire)

December 23, 2020
Thinking about buying stock in Ocugen, Kopin Corp, Mogo Inc, Supernus Pharmaceuticals, or eMagin Corp?

InvestorsObserver issues critical PriceWatch Alerts for OCGN, KOPN, MOGO, SUPN, and EMAN. https://mma.prnewswire.com/media/1333368/InvestorsObserver_Logo.jpg To see how InvestorsObserver's proprietary scoring system rates these stocks, view the...(PR Newswire)

November 26, 2020
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN

Pomerantz LLP is investigating claims on behalf of investors of Supernus Pharmaceuticals, Inc. ("Supernus or the "Company") (NASDAQ: SUPN). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext...(Globe Newswire)

November 22, 2020
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN

Pomerantz LLP is investigating claims on behalf of investors of Supernus Pharmaceuticals, Inc. ("Supernus or the "Company") (NASDAQ: SUPN). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext...(Globe Newswire)

November 19, 2020
The Law Offices of Frank R. Cruz Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors

The Law Offices of Frank R. Cruz announces an investigation of Supernus Pharmaceuticals, Inc. ("Supernus" or the "Company") (NASDAQ: SUPN) on behalf of investors concerning the Company's possible violations of federal securities laws. (BusinessWire)

November 18, 2020
Supernus to Participate in Annual Piper Sandler Healthcare Conference

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company's management will participate in...(Globe Newswire)

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors

Glancy Prongay & Murray LLP ("GPM"), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Supernus Pharmaceuticals, Inc. ("Supernus" or the "Company") (NASDAQ: SUPN) investors...(BusinessWire)

November 16, 2020
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN

Pomerantz LLP is investigating claims on behalf of investors of Supernus Pharmaceuticals, Inc. ("Supernus or the "Company") (NASDAQ: SUPN). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext...(Globe Newswire)

November 11, 2020
Supernus to Present at Two November Investor Conferences

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company's management will present an...(Globe Newswire)

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN

Pomerantz LLP is investigating claims on behalf of investors of Supernus Pharmaceuticals, Inc. ("Supernus or the "Company") (NASDAQ: SUPN). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext...(PR Newswire)

November 09, 2020
Supernus Provides Regulatory Updates for SPN-812 and SPN-830

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced regulatory updates for SPN-812 (viloxazine...(Globe Newswire)

November 04, 2020
Supernus Pharmaceuticals, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / November 4, 2020 / Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) will be discussing their earnings results in their 2020 Third Quarter Earnings call to be held on November 4, 2020 at 9:00 AM Eastern Time. (Accesswire)

October 27, 2020
Supernus to Host Third Quarter 2020 Financial Results Conference Call

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report business...(Globe Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.